Biopharmaceutical News and Research

RSS

Harbour BioMed and Viva Biotech announce strategic collaboration to promote incubation of biotech startups

Harbour BioMed, a global clinical stage biopharmaceutical company and Viva Biotech (Shanghai) Ltd., a world-leading structure-based drug discovery platform today announced a strategic partnership under which both parties will collate their respective expertise in drug discovery and development to promote the incubation of innovative biotech startups.

31 Jul 2020

Investigational drug shows promising results for treating HNSCC tumors

Head and neck cancer is one of the leading causes of cancer-related deaths worldwide, and squamous cell carcinomas (HNSCC) account for the majority of these cases.

31 Jul 2020

Two young scientists receive Damon Runyon-Sohn Pediatric Cancer Fellowship Award

The Damon Runyon Cancer Research Foundation has named two outstanding young scientists as recipients of the Damon Runyon-Sohn Pediatric Cancer Fellowship Award, committing nearly $500,000 to help address a critical shortage of funding for pediatric cancer research.

30 Jul 2020

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

In a recent bioRxiv paper, a research group from the Marinomed Biotech biopharmaceutical company in Austria showed that a sulfated polysaccharide iota-carrageenan has the propensity to inhibit cell entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using an in vitro neutralization assay.

29 Jul 2020

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale School of Medicine and the biopharmaceutical firm AI Therapeutics have launched a multi-institutional clinical trial of a drug for treating COVID-19.

27 Jul 2020

AI Therapeutics announces start of Phase II clinical trial of potential COVID-19 treatment

AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.

27 Jul 2020

Eikonoklastes Therapeutics announces closing of oversubscribed seed financing

Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases with unmet clinical need, today announced closing of an oversubscribed seed financing.

23 Jul 2020

C-Path gets positive response from FDA for drug-induced skeletal muscle injury safety biomarkers

Critical Path Institute announced today that the Biomarker Qualification Program at the Center for Drug Evaluation and Research in the U.S. Food and Drug Administration issued a positive response to the Letter of Intent developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.

23 Jul 2020

Ashion Analytics and Elevation Oncology form innovative cancer treatment partnership

Ashion Analytics LLC today announced a partnership with Elevation Oncology, a clinical stage biopharmaceutical company, focused on the matching of patients with tumors harboring an NRG1 gene fusion identified using Ashion's proprietary GEM ExTra test with CRESTONE, a registration-directed Phase 2 study sponsored by Elevation Oncology.

23 Jul 2020

Sartorius raises 2020 sales and earnings forecast based on dynamic performance in the first half

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, raised its growth and earnings guidance for the current year based on its very dynamic business performance in the first six months of 2020, as well as on high demand expected to continue for the rest of the current fiscal year.

From Sartorius 22 Jul 2020

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).

22 Jul 2020

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.

From Fluidic Sciences and Sphere Bio 20 Jul 2020

Stand Up To Cancer announces new effort to achieve health equity for underserved lung cancer patients

Stand Up To Cancer today announced a new $5 million grant from Bristol Myers Squibb to fund research and education efforts aimed at achieving health equity for underserved lung cancer patients, including Black people and people living in rural communities.

16 Jul 2020

MD Anderson and Sanofi collaborate to accelerate development of innovative cancer therapies

The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune therapies, for patients with cancer.

14 Jul 2020

Altimmune announces positive preclinical results of intranasal COVID-19 vaccine candidate

Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.

13 Jul 2020

BIA Separations signs new distribution agreements with two companies in Asia

BIA Separations, a leading bio-chromatography development and manufacturing company, today announced it has signed agreements with Bioscience companies, GeneX India Biosciences Pvt. Ltd. and IT Technologies Pte. Ltd.

9 Jul 2020

Study sheds new light on protein movement

Many of the most promising medicines under development are proteins, often antibodies, to help patients fight disease. These proteins must be purified as part of the manufacturing process - a task that can be tricky and result in costly waste.

8 Jul 2020

Rigaku Analytical Devices to present during Thai Industrial Pharmacist Association (TIPA) webinar

Rigaku Analytical Devices, the market leader in handheld 1064nm Raman technology, will present its solution for raw material identification during a webinar hosted by the Thai Industrial Pharmacist Association on July 16, 2020 at 9:30 am ICT / 8:30 pm EDT.

From Rigaku Analytical Devices 6 Jul 2020

New agreements to increase access to cancer medicines and save countless lives

The American Cancer Society and the Clinton Health Access Initiative (CHAI) today announced agreements with pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59 percent for medicines procured through the agreements.

29 Jun 2020

USask researchers receive $900,000 to help strengthen Canada's rapid response to COVID-19

The Canadian Institutes of Health Research has awarded three University of Saskatchewan research teams a total of $900,000 to help strengthen Canada's rapid response to the COVID-19 pandemic which had killed more than 450,000 people worldwide.

25 Jun 2020

Biopharmaceutical News and Research

Harbour BioMed and Viva Biotech announce strategic collaboration to promote incubation of biotech startups

Investigational drug shows promising results for treating HNSCC tumors

Two young scientists receive Damon Runyon-Sohn Pediatric Cancer Fellowship Award

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

AI Therapeutics announces start of Phase II clinical trial of potential COVID-19 treatment

Eikonoklastes Therapeutics announces closing of oversubscribed seed financing

C-Path gets positive response from FDA for drug-induced skeletal muscle injury safety biomarkers

Ashion Analytics and Elevation Oncology form innovative cancer treatment partnership

Sartorius raises 2020 sales and earnings forecast based on dynamic performance in the first half

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Stand Up To Cancer announces new effort to achieve health equity for underserved lung cancer patients

MD Anderson and Sanofi collaborate to accelerate development of innovative cancer therapies

Altimmune announces positive preclinical results of intranasal COVID-19 vaccine candidate

BIA Separations signs new distribution agreements with two companies in Asia

Study sheds new light on protein movement

Rigaku Analytical Devices to present during Thai Industrial Pharmacist Association (TIPA) webinar

New agreements to increase access to cancer medicines and save countless lives

USask researchers receive $900,000 to help strengthen Canada's rapid response to COVID-19

Event guide: World ADC San Diego eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News